Franklin Resources Inc. Has $55.34 Million Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Franklin Resources Inc. lifted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 2.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,869,632 shares of the company’s stock after purchasing an additional 87,262 shares during the period. Franklin Resources Inc. owned 3.84% of Day One Biopharmaceuticals worth $55,336,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after acquiring an additional 7,668 shares during the last quarter. SG Americas Securities LLC bought a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $113,000. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals during the 2nd quarter valued at $124,000. Finally, Hsbc Holdings PLC bought a new position in Day One Biopharmaceuticals during the second quarter worth $163,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Trading Down 1.0 %

Shares of DAWN stock opened at $12.62 on Tuesday. The stock has a 50 day simple moving average of $14.17 and a 200 day simple moving average of $14.04. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.94 and a 1 year high of $18.07. The stock has a market cap of $1.27 billion, a P/E ratio of -12.25 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same period last year, the company posted ($0.54) earnings per share. Analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.88 EPS for the current year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $16.10, for a total value of $161,000.00. Following the sale, the insider now owns 1,057,535 shares of the company’s stock, valued at approximately $17,026,313.50. This trade represents a 0.94 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 51,745 shares of company stock worth $748,567 over the last ninety days. Corporate insiders own 8.40% of the company’s stock.

Analysts Set New Price Targets

DAWN has been the topic of several research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals has a consensus rating of “Buy” and an average price target of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.